{"id":7770,"date":"2018-10-15T18:01:26","date_gmt":"2018-10-15T22:01:26","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/what-you-should-know-about-fourniers-gangrene\/"},"modified":"2022-08-18T21:16:13","modified_gmt":"2022-08-19T01:16:13","slug":"ce-qu-il-faut-savoir-de-fourniers-gangrene","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/fr\/article\/ce-qu-il-faut-savoir-de-fourniers-gangrene\/","title":{"rendered":"Ce que vous devez savoir sur la gangr\u00e8ne de Fournier"},"content":{"rendered":"

La Food and Drug Administration (FDA) des \u00c9tats-Unis<\/a> a \u00e9mis un avertissement fin ao\u00fbt 2018 concernant le lien entre les m\u00e9dicaments contre le diab\u00e8te et une maladie rare, mais potentiellement mortelle, appel\u00e9e gangr\u00e8ne de Fournier. L'avertissement est sp\u00e9cifique \u00e0 certains inhibiteurs approuv\u00e9s par la FDA (SGLT2), qui sont cens\u00e9s pr\u00e9venir les reins<\/a> de la r\u00e9absorption du sucre dans le sang, contribuant ainsi \u00e0 r\u00e9duire la glyc\u00e9mie et le risque de crise cardiaque et d'accident vasculaire c\u00e9r\u00e9bral chez les adultes atteints diab\u00e8te de type 2<\/a>. These medications include, but are not limited to, Invokana, Jardiance, and other SGLT2 inhibitors produced and distributed by global pharmaceutical companies. The warning was issued as a result of 12 confirmed cases of Fournier\u2019s gangrene linked to taking SGLT2 inhibitors between March 2013 and May 2018. The FDA\u2019s warning states that while there are only 12 confirmed cases linked to SGLT2 inhibitors, to include seven men and five women, the estimated 1.7 million patients who were prescribed these inhibitors in 2017 may potentially be at risk. The pharmaceutical attorneys at Napoli Shkolnik , along with the FDA, urge any individuals who are or may be experiencing symptoms to seek medical attention immediately. For patients and health professionals who notice side effects from using SGLT2 inhibitors, the FDA requests that you report your symptoms to the Surveillance m\u00e9dicale de la FDA<\/a> programme de d\u00e9claration tout de suite.<\/p>\n

Today, the pharmaceutical lawyers at Napoli Shkolnik will share useful statistics and facts, and explain the risk factors and symptoms of Fournier\u2019s gangrene. Should you or a loved one fall under the common risk factors or display symptoms, contact a health professional immediately. Then, reach out to Napoli Shkolnik \u2019s dedicated contentieux pharmaceutique<\/a> \u00e9quipe pour discuter de votre r\u00e9clamation potentielle.<\/p>\n

Comprendre la gangr\u00e8ne de Fournier<\/h2>\n

Les Clinique Mayo<\/a> d\u00e9finit la gangr\u00e8ne comme la "mort des tissus corporels due \u00e0 un manque de circulation sanguine ou \u00e0 une infection bact\u00e9rienne grave", qui affecte g\u00e9n\u00e9ralement les extr\u00e9mit\u00e9s. La gangr\u00e8ne de Fournier est une infection n\u00e9crosante<\/a> c'est extr\u00eamement rare, mais souvent d\u00e9figurant et m\u00eame mortel. Cette infection bact\u00e9rienne grave affecte les tissus sous la peau entourant les tissus mous (muscles, nerfs, vaisseaux sanguins et graisse) des organes g\u00e9nitaux ; plus pr\u00e9cis\u00e9ment, le p\u00e9rin\u00e9e entre la vulve et le scrotum. Alors que la gangr\u00e8ne de Fournier affecte g\u00e9n\u00e9ralement les hommes, il y a eu des cas connus chez les femmes et les enfants.<\/p>\n

Statistiques et faits utiles<\/h3>\n